IAP6 Roo'd PCT 30 MAR 2006

Docket No.: NHL-NP-49-NP

Serial No.: 10/528,748 Customer No.: 00432

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**EXAMINER:** 

(NOT YET RECEIVED)

ART UNIT:

(NOT YET RECEIVED)

SERIAL NO.:

10/528,748

FILING DATE:

March 22, 2005

INVENTORS:

Claas JUNGHANS, Matthias SCHROFF, Christiane

JUHLS, and Detlef OSWALD

TITLE:

VACCINE AGAINST ONCOVIRUS INFECTIONS, SUCH

AS INFECTIONS BY FELINE LEUKOSIS

VIRUS OF THE CAT

Greensburg, Pennsylvania 15601

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

March 27, 2006

### TRANSMITTAL LETTER

Sir:

Please find enclosed herewith the following documents relating to the above-cited case:

- 1) an Information Disclosure Statement (Form PTO-1449) having two pages;
- copies of art (10) cited in the Information Disclosure Statement;
- 3) a copy of an International Search Report from the corresponding International application and an English translation thereof; and
- 4) a stamped, self-addressed postcard, return of which is requested to acknowledge receipt of the enclosed documents.

1

Docket No.: NHL-NP-49-NP Serial No.: 10/528,748 Customer No.: 00432

## TRANSMITTAL LETTER Page 2

It is believed that no fee is required to file the enclosed documents.

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on <u>March 27, 2006</u>.

Respectfully submitted,

Nils H. Ljungman, Esq. Attorney for Applicant(s)

Reg. No. 25,997

Nils H. Ljungman & Associates

P.O. Box 130

Greensburg, PA 15601-0130 Telephone: (724) 836-2305

Facsimile: (724) 836-2313

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on March 27, 2006.

Signature

Vivian W. Toohey

Name of person mailing paper or fee

March 27, 2006

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use Several Sheets if Necessary)

of

1

Sheet

Application Number 10/528,748

Filing Date MARCH 22, 2005

SURE First Named Inventor CLAAS JUNGHANS

Art Unit (NOT YET RECEIVED)

Examiner Name (NOT YET RECEIVED)

Attorney Docket No. NHL-NP-49-NP

2 IDS Mailing Date MARCH 27, 2006

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant
		Number-Kind Code			Passages or Relevant Figures Appear
	AA	US - 6,248,582 B1	06-19-2001	KHAN ET AL.	
	AB	US - 6,348,196 B1	02-19-2002	AUDONNET ET AL.	
	AC	US -			
	AD	US -			
	AE	US -			
	AF	US -			
	AG	US -			
	AH	US -			
	Al	US -			
	AJ	US -			
	AK	US -			

#### **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of	Translation	
		Country Code-Number-Kind Code	MM-DD-YYYY	Cited Document	YES	NO
	AL	WO98/21322	05-22-1998	WITTIG ET AL.	X (ABSTR)	
·	AM	WO00/15824	03-23-2000	BRANDÉN ET AL.	Х	
	AN	EP0216564	04-01-1987	NUNBERG ET AL.	Х	
	AO	WO03/031470A2	04-17-2003	FUERTES ET AL.	X (ABSTR)	_
	AP					
	AQ					
	AR		***			
	AS			· · · · · · · · · · · · · · · · · · ·		

#### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

AT	"PROTECTION OF CATS AGAINST FELINE LEUKEMIA VIRUS BY VACCINATION WITH A CANARYPOX VIRUS RECOMBINANT, ALVAC-FL," TARTAGLIA ET AL., JOURNAL OF VIROLOGY, APR. 1993, P. 2370-2375, VOL. 67, NO. 4.
AU	"DEVELOPMENT OF A GENETICALLY ENGINEERED VACCINE AGAINST FELINE LEUKEMIA VIRUS INFECTION," KENSIL ET AL., JAVMA, VOL. 199, NO. 10, NOVEMBER 15, 1991, P. 1423-1427.
 AV	"NEW HOPE FOR AN AIDS VACCINE," H.L. ROBINSON, NATURE REVIEWS, IMMUNOLOGY, VOL. 2, APRIL 2002, P. 239-250.
AW	"INCREASED EXPRESSION AND IMMUNOGENICITY OF SEQUENCE-MODIFIED HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 GAG GENE," MEGEDE ET AL., JOURNAL OF VIROLOGY, MAR. 2000, P. 2628-2635, VOL. 74, NO. 6.
 <del> </del>	

Examiner Signature Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/528,748

Filing Date MARCH 22, 2005

First Named Inventor CLAAS JUNGHANS

Art Unit (NOT YET RECEIVED)

Examiner Name (NOT YET RECEIVED)

Attorney Docket No. NHL-NP-49-NP

IDS Mailing Date MARCH 27, 2006

(Use Several Sheets if Necessary)				Examiner Name	(NOT YET RECEIVED)
	(036 06 46 181 0	ileets ii i	vecessary,	Attorney Docket No.	NHL-NP-49-NP
Sheet	2	of	2	IDS Mailing Date	MARCH 27, 2006

#### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code				
	AA	US -				
	AB	US -				
	AC	US -				
	AD	US -				
	AE	US -				
	AF	US -				
	AG	US -				
	АН	US -				
	Al	US -				
	AJ	US -				
•	AK	us -				

#### **FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of	Translation	
		Country Code-Number-Kind Code	MM-DD-YYYY	Cited Document	YES	NO
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					
	AR					-
	AS					

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)
AT'	"HUMAN IMMUNODEFICIENCY VIRUS TYPE 1-SPECIFIC IMMUNITY AFTER GENETIC IMMUNIZATION IS ENHANCED BY MODIFICATION OF GAG AND POL EXPRESSION," HUANG ET AL., JOURNAL OF VIROLOGY, MAY 2001, P. 4947-4951, VOL. 75, NO. 10.
AU'	"FELINE LEUKAEMIA VIRUS: PROTECTIVE IMMUNITY IS MEDIATED BY VIRUS-SPECIFIC CYTOTOXIC T LYMPHOCYTES," FLYNN ET AL., IMMUNOLOGY 2000, 101, P. 120-125.
AV	
AW	
Examiner Signature	Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.